Pedictors of Perianal Fistula Relapse in Crohn’s Disease.

Pedictors of Perianal Fistula Relapse in Crohn’s Disease. Inflamm Bowel Dis. 2019 Aug 30;: Authors: Malian A, Rivière P, Bouchard D, Pigot F, Eléouet-Kaplan M, Favreau-Weltzer C, Poullenot F, Laharie D Abstract BACKGROUND: Despite an optimal medico-surgical management of perineal Crohn’s disease (PCD), fistula relapse still occurs in 30% of patients. Our aim was to determine predictors of fistula relapse in patients in remission after treatment of a PCD lesion. METHODS: Consecutive patients treated for fistulizing PCD have been included in a retrospective study when they achieved fistula remission within…

Read More

Assessing Small Bowel Stricturing and Morphology in Crohn’s Disease Using Semi-automated Image Analysis.

Assessing Small Bowel Stricturing and Morphology in Crohn’s Disease Using Semi-automated Image Analysis. Inflamm Bowel Dis. 2019 Aug 29;: Authors: Stidham RW, Enchakalody B, Waljee AK, Higgins PDR, Wang SC, Su GL, Wasnik AP, Al-Hawary M Abstract BACKGROUND: Evaluating structural damage using imaging is essential for the evaluation of small intestinal Crohn’s disease (CD), but it is limited by potential interobserver variation. We compared the agreement of enterography-based bowel damage measurements collected by experienced radiologists and a semi-automated image analysis system. METHODS: Patients with small bowel CD undergoing a CT-enterography…

Read More

Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab.

Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab. Inflamm Bowel Dis. 2019 Aug 29;: Authors: Barberio B, D’Incà R, Facchin S, Dalla Gasperina M, Fohom Tagne CA, Cardin R, Ghisa M, Lorenzon G, Marinelli C, Savarino EV, Zingone F Abstract BACKGROUND AND AIMS: Inflammatory bowel diseases (IBDs) are treated with anti-TNF agents. Strategies to monitor response to therapy may improve clinical control of the disease and reduce economical costs. Previous evidence suggests cleavage of infliximab (IFX) by Matrix Metalloproteinase 3 (MMP3) as a mechanism…

Read More

The Changing Epidemiology of Inflammatory Bowel Disease: What Goes Up May Come Down.

The Changing Epidemiology of Inflammatory Bowel Disease: What Goes Up May Come Down. Inflamm Bowel Dis. 2019 Aug 23;: Authors: Khalili H Abstract Recent epidemiologic studies have shown that although the incidence of inflammatory bowel disease (IBD) is rapidly increasing in newly industrialized countries, at the turn of the 21st century the incidence had stabilized in the Western world. In this issue of Inflammatory Bowel Diseases, Torabi and colleagues present their findings on the temporal trends and geographic variations in IBD incidence in Manitoba from 1990 to 2012 using the…

Read More

The Association of Medications and Vaccination with Risk of Pneumonia in Inflammatory Bowel Disease.

The Association of Medications and Vaccination with Risk of Pneumonia in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Aug 27;: Authors: Gregory MH, Ciorba MA, Wiitala WL, Stidham RW, Higgins P, Morley SC, Hou JK, Feagins LA, Govani SM, Cohen-Mekelburg SA, Waljee AK Abstract BACKGROUND: Patients with inflammatory bowel disease (IBD) are at increased risk for pneumonia, and corticosteroids are reported to amplify this risk. Less is known about the impact of corticosteroid-sparing IBD therapies on pneumonia risk or the efficacy of pneumococcal vaccination in reducing all-cause pneumonia in real-world…

Read More

Impaired Inactivation of Digestive Proteases in Lower Gut Due to Inhibition of Gut Bacteria by Food Additives Such as Saccharin and Sucralose as Main Cause of Inflammatory Bowel Disease: A Two-Decades-Long Hypothesis Warrants Testing.

Impaired Inactivation of Digestive Proteases in Lower Gut Due to Inhibition of Gut Bacteria by Food Additives Such as Saccharin and Sucralose as Main Cause of Inflammatory Bowel Disease: A Two-Decades-Long Hypothesis Warrants Testing. Inflamm Bowel Dis. 2019 Aug 24;: Authors: Qin X PMID: 31504530 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31504530?dopt=Abstract

Read More

Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn’s Disease.

Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn’s Disease. Inflamm Bowel Dis. 2019 Aug 30;: Authors: George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V Abstract BACKGROUND: We summarized the protocol-specified corticosteroid tapering regimens in clinical trials of moderate-severe ulcerative colitis (UC) and Crohn’s disease (CD) and calculated differences in rates of clinical remission vs corticosteroid-free clinical remission (CSF-CR). METHODS: Through a systematic literature review through February 28, 2019, we identified 16 randomized controlled trials (RCTs) of…

Read More

Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial.

Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial. Inflamm Bowel Dis. 2019 Aug 24;: Authors: Caldera F, Hillman L, Saha S, Wald A, Grimes I, Zhang Y, Sharpe AR, Reichelderfer M, Hayney MS Abstract BACKGROUND: Patients with inflammatory bowel disease (IBD) on anti-tumor necrosis factor alpha (TNF) agents may have lower immune response to the influenza vaccine. We aimed to evaluate the immunogenicity of the high dose (HD) vs standard dose (SD) influenza vaccine in patients with IBD on…

Read More

Application of Herbaceous Medications for Inflammatory Bowel Disease as a Complementary and Alternative Therapy.

Application of Herbaceous Medications for Inflammatory Bowel Disease as a Complementary and Alternative Therapy. Inflamm Bowel Dis. 2019 Aug 31;: Authors: Lin Z, Wu H, Fu Y, Dai S Abstract BACKGROUND: Conventional medicine for the treatment of IBD is prevailingly composed of sulfadiazine, 5-aminosalicylic acid, glucocorticoid, and immunosuppressants, which have the merits of alleviating intestine inflammation, but long-term use of these drugs may cause toxic side effects; additionally, these drugs may be expensive. In the pursuit of novel and more economic therapies, patients may increasingly look at complementary and alternative…

Read More
<< Go Back